A single-center , open-label , randomized , multiple-dose , three-treatment , three-sequence , crossover study was performed in 24 healthy male subjects , aged 22-48 years , who randomly received one of the following treatments for 4 days in each period : itopride 150 mg ER once daily under fasting or fed conditions , or itopride 50 mg IR three times daily in the fasting state .